# A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

> **NCT04714190** · PHASE3 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 351 (estimated)

## Conditions studied

- Gastric Cancer
- HER2 Overexpressing Gastric Carcinoma

## Interventions

- **DRUG:** RC48-ADC
- **DRUG:** Paclitaxel injection
- **DRUG:** Irinotecan Hydrochloride Injection
- **DRUG:** Apatinib Mesylate Tablets

## Key facts

- **NCT ID:** NCT04714190
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-24
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-06-30
- **Target enrollment:** 351 (ESTIMATED)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04714190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04714190, "A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04714190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*